A

Agios Pharmaceuticals
D

AGIO

55.670
USD
0.13
(0.23%)
Market Closed
Volume
12,400
EPS
-6
Div Yield
-
P/E
5
Market Cap
3,174,870,956
Related Instruments
    B
    BLUE
    -0.04270
    (-11.74%)
    0.32090 USD
    E
    EXEL
    -0.600
    (-1.71%)
    34.450 USD
    I
    INCY
    -1.840
    (-2.37%)
    75.890 USD
    More
News

Title: Agios Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.